{
  "id": 19750142,
  "title": "Larimar Therapeutics chief development officer buys $13,549 in stock",
  "url": "https://urgent.news/2026/11/13/larimar-therapeutics-chief-development-officer-buys-13-549-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-13T03:31:17.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/larimar-therapeutics-chief-development-officer-buys-13549-in-stock-93CH-5024035"
  },
  "original_language": "en",
  "account": "Gopi Shankar, the Chief Development Officer at Larimar Therapeutics, Inc., made a significant move in the company's stock on November 11, 2026. This insider purchase involved acquiring 5,000 shares at a price of $2.7098 per share, totaling $13,549. Following this transaction, Mr. Shankar now holds a total of 81,443 shares of the company's common stock.\n\nThe stock's performance has been noteworthy, with a nearly 13% return over the past week, according to InvestingPro data. The current trading price of $2.70 reflects a 41% increase from its 52-week low of $1.92, and it remains significantly below its 52-week high of $6.42. Analysts suggest the stock may be undervalued, with further analysis available to subscribers.\n\nRecently, Larimar Therapeutics also announced the appointment of John B. Harlow, Jr. as president and chief operating officer, effective immediately. Mr. Harlow brings a wealth of experience from his previous roles at companies such as Esperion Therapeutics, Melinta Therapeutics, Baudax Bio, and Recro Pharma.\n\nAdditionally, Wedbush has maintained its Outperform stock rating for Larimar Therapeutics, maintaining a price target of $11.00. This rating is based on the potential approval of Larimar's nomlabofusp, which is believed to have a significant impact on disease progression in Friedreich's ataxia. These developments highlight the company's strategic leadership changes and its ongoing potential in the therapeutic market.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}